Sort
10,766 grants matching “checkpoint inhibitor”
Understanding how T cell intrinsic androgen receptor activity influences cell differentiation and dysfunction
$548,342Amy E Moran · Oregon Health & Science University · R37 · FY2021 · CA
The Microbiome and Mucosal Immunity in Cervical Cancer Disparities
$548,284Adam Burgener · Case Western Reserve University · R01 · FY2023 · CA
Utilizing MEK Inhibition to Sensitize Microsatellite Stable Colorectal Cancer to Immune Checkpoint Therapy
$548,097Christopher Hanyoung Lieu · University Of Colorado Denver · R01 · FY2020 · CA
Overcoming primary and secondary resistance in wild-type BRAF melanoma
$548,033Andrew E Aplin · Wistar Institute · P01 · FY2020 · CA
Plk1 as a prognostic biomarker for prostate cancer
$548,025Xiaoqi Liu · University Of Kentucky · R01 · FY2021 · CA
Pathogenesis of Immune checkpoint inhibitors-induced myocarditis
$547,945Daniela Cihakova · Johns Hopkins University · R01 · FY2025 · CA
Nanoconjugate delivery of proliferation and checkpoint inhibitors to treat glial tumors
$547,857Julia Y Ljubimova · Cedars-Sinai Medical Center · R01 · FY2018 · CA
Okazaki fragment maturation: mutagenesis and cell survival
$547,800Binghui Shen · Beckman Research Institute/City Of Hope · R01 · FY2023 · CA
Okazaki fragment maturation: mutagenesis and cell survival
$547,800Binghui Shen · Beckman Research Institute/City Of Hope · R01 · FY2025 · CA
Identification of REV-ERB inverse agonists for cancer immunotherapy
$547,678Laura A Solt · Scripps Florida · R01 · FY2019 · CA
Functional and Therapeutic Significance of PLK4 in Melanoma
$547,582Nihal Ahmad · University Of Wisconsin-Madison · R01 · FY2022 · CA
Functional and Therapeutic Significance of PLK4 in Melanoma
$547,582Nihal Ahmad · University Of Wisconsin-Madison · R01 · FY2025 · CA
Targeting the vasculature to enhance anti-tumor immunity
$547,081Andrew Carl Dudley · University Of Virginia · R01 · FY2025 · CA
Project 1- Elucidating oncogenic KRAS in PDAC cell signaling, resistance and immunity
$546,753Ronald Anthony Depinho · University Of Tx Md Anderson Can Ctr · P01 · FY2023 · CA
An urinary drug disposing approach for treatment of bladder Cancer
$546,617Benedict Shek Hang Law · Weill Medical Coll Of Cornell Univ · R01 · FY2025 · CA
Developing translationally-relevant genetically engineered mouse models of lung adenocarcinoma for investigations in cancer immunology
$546,612Nikhil Joshi · Yale University · R01 · FY2023 · CA
A novel signaling mechanism for LRP5
$546,536Dianqing Wu · Yale University · R01 · FY2025 · CA
A novel signaling mechanism for LRP5
$546,536Dianqing Wu · Yale University · R01 · FY2022 · CA
Project 1: Multi-scale modeling of adaptive drug resistance in BRAF-mutant melanoma
$546,237Peter Karl Sorger · Harvard Medical School · U54 · FY2021 · CA
Interrogating Type I Interferon signaling in breast cancer brain metastasis
$546,142Qing Chen · Research Inst Of Fox Chase Can Ctr · R01 · FY2025 · CA
Systemic RNA Delivery to Tumors
$546,127Jinjun Shi · Brigham And Women'S Hospital · R01 · FY2025 · CA
Systemic RNA Delivery to Tumors
$546,127Jinjun Shi · Brigham And Women'S Hospital · R01 · FY2023 · CA
Studies of Materials with Physiological Properties
$546,026Harvard University · R01 · FY2004 · GM
PD-1 blockade with cryoablation and dendritic vaccine to treat lymphoma
$545,997Yi Lin · Mayo Clinic Rochester · R01 · FY2017 · CA
Towards Translation of MU-CN29: New Therapeutic Nanoparticle for Drug-Resistant NSCLC
$545,975Raghuraman Kannan · University Of Missouri-Columbia · R01 · FY2024 · CA